Physician profile
Paul Smithson
NPI 1780383109
$1,993.24
in general payments reported to CMS, 2019-2025
23 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $801 · 2024: $984 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402 · Education: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.31 |
| Education | $590.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $399.14 | 2023-2025 | |
| Astellas Pharma US INC | $312.08 | 2023-2024 | Xospata, Padcev, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $176.66 | 2023-2025 | Opdivo, Krazati |
| Seagen INC. | $160.72 | 2023 | Adcetris, Tivdak, Padcev |
| Gilead Sciences, INC. | $103.30 | 2023-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $84.41 | 2023-2024 | |
| Lilly USA, LLC | $71.21 | 2023-2025 | Jaypirca, Verzenio |
| Janssen Biotech, INC. | $70.40 | 2023-2024 | Erleada |
| Myriad Genetic Laboratories, INC. | $66.71 | 2024-2025 | Myrisk |
| Abbvie INC. | $62.25 | 2023-2024 | |
| Amgen INC. | $59.61 | 2023 | Nplate, Vectibix, Xgeva |
| Regeneron Healthcare Solutions, INC. | $53.99 | 2023-2024 | Libtayo |
| Daiichi Sankyo INC. | $53.98 | 2023-2025 | Enhertu |
| Stemline Therapeutics INC. | $53.02 | 2023-2024 | Orserdu |
| Puma Biotechnology, INC. | $51.19 | 2023-2024 | Nerlynx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $43.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $36.05 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $30.16 | 2023-2024 | Keytruda, Welireg |
| Genzyme Corporation | $25.41 | 2023 | |
| Mirati Therapeutics, INC. | $25.17 | 2024 | Krazati |
| Sobi, INC | $19.56 | 2025 | |
| Glaxosmithkline, LLC. | $18.11 | 2024 | Ojjaara |
| Cti Biopharma Corp. | $16.63 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smithson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.